Dashboard
Financial statements
VTRS

Company financials

Viatris

Health Care Pharmaceuticals Pittsburgh, Pennsylvania Last filing Feb 26, 2026 · FY2025
Revenue FY2025
$14.3B
3y CAGR -4.2% P8
Net income FY2025
$-3.5B
Net margin -24.6% P4
Total assets FY2025
$37.2B
ROA -9.5% P4
Operating cash flow FY2025
$2.3B
FCF margin +13.5% P41
8 yrs · FY2018–FY2025 9 filed · 0 derived · 0 blank
1Y 3Y 5Y

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

27 accounts · 5 years
Total assets $37.2B
Total liabilities $22.5B
Shareholders equity $14.7B
Account 2025 2024 2023 2022 2021 Trend
Assets
Cash and Cash Equivalents 9.2% 5.0% 6.4% 7.7% 3.9%
Accounts Receivable 21.2% 21.9% 24.0% 23.5% 23.9%
Inventory 28.0% 26.1% 22.5% 21.6% 22.2%
Prepaid Expenses 10.0% 11.6% 13.1% 11.1% 10.9%
Total Current Assets 68.5% 64.6% 84.1% 65.4% 61.0%
Property,Plant and Equipment 18.3% 18.1% 17.9% 18.6% 17.8%
Goodwill 47.2% 62.0% 64.0% 64.1% 67.7%
Intangible Assets 105.6% 115.8% 124.3% 139.0% 146.1%
Deferred Tax Assets 7.4% 5.1% 4.5% 5.7% 7.5%
Other Noncurrent Assets 13.1% 16.0% 14.3% 14.8% 6.5%
Total Assets 260.1% 281.6% 309.1% 307.6% 306.6%
Liabilities
Accounts Payable 12.3% 12.6% 12.6% 10.9% 9.3%
Accrued Liabilities 0.9% 1.3% 1.5% 1.7% 1.3%
Current Portion of Long Term Debt 13.5% 0.1% 12.6% 7.7% 18.8%
Other Current Liabilities 23.0% 25.3% 23.8% 21.2% 25.8%
Total Current Liabilities 49.6% 39.2% 50.4% 41.5% 55.3%
Long Term Debt 87.3% 95.2% 104.9% 110.8% 110.2%
Deferred Tax Liabilities 6.2% 7.5% 11.3% 15.0% 15.7%
Other Noncurrent Liabilities 14.1% 13.2% 9.8% 10.8% 10.8%
Total Liabilities 157.2% 155.1% 176.4% 178.0% 192.0%
Equity
Common Stock 0.1% 0.1% 0.1% 0.1% 0.1%
Additional Paid In Capital 131.5% 128.4% 122.0% 114.7% 103.6%
Retained Earnings -2.7% 23.2% 30.1% 31.8% 20.6%
Treasury Stock 7.0% 3.4% 1.6% 0.0% —
Accumulated Other Comprehensive Income -18.9% — — — -9.8%
Total Stockholders Equity 102.9% 126.4% 132.7% 129.6% 114.6%
Total Liabilitiesand Equity 260.1% 281.6% 309.1% 307.6% 306.6%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 5 years
Ratio 2025 2024 2023 2022 2021
Profitability
Gross margin +35.1% +38.2% +41.7% +40.0% +31.2%
Operating margin -18.6% +0.1% +5.0% +9.9% -0.2%
Net margin -24.6% -4.3% +0.4% +12.8% -7.1%
FCF margin +13.5% +13.4% +16.4% +15.9% +14.3%
Growth
Revenue CAGR (3y) -4.2% -6.2% +8.9% +12.2% +16.1%
Returns
ROE -23.9% -3.4% +0.3% +9.9% -6.2%
ROA -9.5% -1.5% +0.1% +4.2% -2.3%
ROIC -9.6% +0.0% +0.5% +3.1% -0.1%
Liquidity
Current ratio 1.38x 1.65x 1.67x 1.58x 1.10x
Quick ratio 0.61x 0.68x 0.60x 0.75x 0.50x
Leverage
D/E 1.53x 1.23x 1.33x 1.37x 1.68x
Interest coverage -5.65x 0.02x 1.34x 2.73x -0.05x
Efficiency
Asset turnover 0.38x 0.36x 0.32x 0.33x 0.33x
Cash conversion cycle +166d +160d +150d +151d +156d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched
Saving notes adds VTRS to your watchlist.